SEC Filing Summary: Stellar Biotechnologies, Inc. (Form 8-K)
Business Context and Reporting Period
This Form 8-K Current Report was filed by Stellar Biotechnologies, Inc. on November 3, 2015. The registrant is incorporated in British Columbia, Canada, with principal executive offices in Port Hueneme, California. The report discloses a material event regarding the company's stock listing status.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a corporate event and does not contain financial statements or performance metrics.
Material Changes
The primary material change reported is the approval of Stellar Biotechnologies, Inc.'s common shares for listing on the NASDAQ Capital Market. This listing became effective upon the opening of trading on November 5, 2015.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, outlook, or specific risk factors beyond the standard disclosure of the listing event. A press release dated November 3, 2015, is included as Exhibit 99.1 and incorporated by reference.
Key Facts for Investor Verification
- Confirm the effective trading date of November 5, 2015, on the NASDAQ Capital Market.
- Review the full text of the press release (Exhibit 99.1) for additional context on the listing approval.
- Note that the registrant's name in the filing header is Stellar Biotechnologies, Inc., despite the request metadata referencing Edesa Biotech, Inc.
- Verify that no financial data is included in this specific 8-K filing.